focus -WSS

focus

author：focus 2025-09-01 15:10:00 - browse：4

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Congressmen charge Covid hearing ‘could have been an email’

WSS

Some dementia cases could be undiagnosed liver disease

Beam Therapeutics to lay off 20% of its staff, re

UnitedHealth’s board chair also owns a personal investment firm

STAT Readout Newsletter: Today's biggest biotech updates

Juul spent big to court Black leaders to promote its e

ARCH Venture Partners is raising $3 billion for a life sciences fund

focus

focus

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Virginia high school admissions case could be legal follow

What we need to know about Arena Bioworks

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Continuity nursing helped my family in our darkest PICU moments

ARCH Venture Partners is raising $3 billion for a life sciences fund

23andMe had bad news about my health. I wish a person had delivered it

The EU Joint Clinical Assessment needs to live up to its promise

entertainment

The explosion of genetic testing requires a new approach

Covid misinformation case heads to Supreme Court

Medicare drug price negotiation’s day in court

FDA drug safety: Singulair case shows systemic surveillance flaws

Senate committee scrutinizes Medicare Advantage brokers

STAT Summit: GSK CEO on pharma giant's new direction

focus

Wikipedia

focus

focus